Figures & data
Table 1 Baseline characteristics of the 12 studies included
Table 2 Meta-analysis results of associations of decreased miR-101 expression with clinicopathological parameters
Figure 2 Forest plot of studies evaluating HRs of decreased miR-101 expression for OS.
![Figure 2 Forest plot of studies evaluating HRs of decreased miR-101 expression for OS.](/cms/asset/7a185ee2-fc2c-4bc5-818e-7cd816bc5613/dott_a_12195626_f0002_b.jpg)
Table 3 Subgroup analysis of decreased miR-101 for OS in solid tumors
Figure 3 Forest plot of studies evaluating HRs of decreased miR-101 expression for DFS/RFS/PFS.
Abbreviations: DFS, disease-free survival; RFS, recurrence-free survival; PFS, progression-free survival; HR, hazard ratio; OS, overall survival.
![Figure 3 Forest plot of studies evaluating HRs of decreased miR-101 expression for DFS/RFS/PFS.](/cms/asset/56d57191-8de1-4673-9368-c6bee99fc7bd/dott_a_12195626_f0003_c.jpg)
Figure 4 Begg funnel plot for publication-bias test of overall survival.
![Figure 4 Begg funnel plot for publication-bias test of overall survival.](/cms/asset/7cce1259-6bbd-4528-b917-c5dad38b37bf/dott_a_12195626_f0004_b.jpg)
Figure 5 Sensitivity analysis of relationship between decreased miR-101 expression and overall survival in cancers.
![Figure 5 Sensitivity analysis of relationship between decreased miR-101 expression and overall survival in cancers.](/cms/asset/27076f80-d52a-40d1-ba5b-e87ee9f8a25b/dott_a_12195626_f0005_b.jpg)
Table 4 Gene targets of miR-101 in this meta-analysis